Nina Bijker

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Is DCIS breast cancer, and how do I treat it?
    N Bijker
    Department of Radiation Oncology, Academic Medical Center, P O Box 22700, 1100DE, Amsterdam, The Netherlands
    Curr Treat Options Oncol 14:75-87. 2013
  2. doi request reprint Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective
    Nina Bijker
    Department of Radiotherapy, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands
    J Natl Cancer Inst Monogr 2010:178-80. 2010
  3. doi request reprint Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial
    Mila Donker
    Mila Donker, Harry Bartelink, and Emiel J T Rutgers, The Netherlands Cancer Institute Nina Bijker, Academic Medical Center, Amsterdam, the Netherlands Saskia Litière, Gustavo Werutsky, and Nicole Duez, European Organisation for Research and Treatment of Cancer EORTC, Brussels, Belgium Jean Pierre Julien, Centre Henri Becquerel, Rouen Philippe Rouanet, Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Montpellier Christine Tunon de Lara, Bergonie Institute, Bordeaux, France Ian S Fentiman, Guy s Hospital, London, United Kingdom and Roberto Agresti, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 31:4054-9. 2013
  4. ncbi request reprint [Partial breast irradiation (PBI): the therapy of the future?]
    Caro C E Koning
    Academisch Medisch Centrum, Afd Radiotherapie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A2593. 2010

Collaborators

Detail Information

Publications4

  1. doi request reprint Is DCIS breast cancer, and how do I treat it?
    N Bijker
    Department of Radiation Oncology, Academic Medical Center, P O Box 22700, 1100DE, Amsterdam, The Netherlands
    Curr Treat Options Oncol 14:75-87. 2013
    ....
  2. doi request reprint Local and systemic outcomes in DCIS based on tumor and patient characteristics: the radiation oncologist's perspective
    Nina Bijker
    Department of Radiotherapy, Academic Medical Centre, PO Box 22660, 1100 DD Amsterdam, The Netherlands
    J Natl Cancer Inst Monogr 2010:178-80. 2010
    ..The optimal radiotherapy dose in BCT for DCIS has yet to be established. Also, at present, a subgroup of lesions in which the recurrence rate is so low that radiotherapy can be safely omitted has not yet been identified...
  3. doi request reprint Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial
    Mila Donker
    Mila Donker, Harry Bartelink, and Emiel J T Rutgers, The Netherlands Cancer Institute Nina Bijker, Academic Medical Center, Amsterdam, the Netherlands Saskia Litière, Gustavo Werutsky, and Nicole Duez, European Organisation for Research and Treatment of Cancer EORTC, Brussels, Belgium Jean Pierre Julien, Centre Henri Becquerel, Rouen Philippe Rouanet, Centre Regional de Lutte Contre le Cancer, Val d Aurelle, Montpellier Christine Tunon de Lara, Bergonie Institute, Bordeaux, France Ian S Fentiman, Guy s Hospital, London, United Kingdom and Roberto Agresti, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
    J Clin Oncol 31:4054-9. 2013
    ..We analyzed the long-term risk on developing LR and its impact on survival after local treatment for DCIS...
  4. ncbi request reprint [Partial breast irradiation (PBI): the therapy of the future?]
    Caro C E Koning
    Academisch Medisch Centrum, Afd Radiotherapie, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 154:A2593. 2010
    ..report the same favourable local recurrence rates following PBI with single dose intraoperative radiotherapy as with whole-breast irradiation. As the follow-up period so far has been short, long-time results should be awaited...